KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Debt: 2009-2017

Historic Total Debt for Arbutus Biopharma (ABUS) over the last 3 years, with Dec 2017 value amounting to $12.0 million.

  • Arbutus Biopharma's Total Debt changed negligibly% to $12.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $12.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $12.0 million for FY2017, which is negligibly% changed negligibly from last year.
  • As of Q4 2017, Arbutus Biopharma's Total Debt stood at $12.0 million, which was down 0.00% from $12.0 million recorded in Q3 2017.
  • In the past 5 years, Arbutus Biopharma's Total Debt ranged from a high of $1,723.9 billion in Q4 2013 and a low of $1.7 million during Q3 2013.
  • In the last 2 years, Arbutus Biopharma's Total Debt had a median value of $12.0 million in 2017 and averaged $12.0 million.
  • Data for Arbutus Biopharma's Total Debt shows a maximum YoY decreased of 2.65% (in 2013) over the last 5 years.
  • Arbutus Biopharma's Total Debt (Quarterly) stood at $1,723.9 billion in 2013, then reached $12.0 million in 2016, then remained steady at $12.0 million in 2017.
  • Its Total Debt was $12.0 million in Q4 2017, compared to $12.0 million in Q3 2017 and $12.0 million in Q2 2017.